{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T04:13:08Z","timestamp":1784693588727,"version":"3.55.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T00:00:00Z","timestamp":1576540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anti-VEGF antibody bevacizumab has shown efficacy for the treatment of neurofibromatosis type 2 (NF2). Theoretically, vascular endothelial growth factor receptors (VEGFRs)-specific cytotoxic T lymphocytes (CTLs) can kill both tumor vessel cells and tumor cells expressing VEGFRs. Here we show an exploratory clinical study of VEGFRs peptide vaccine in seven patients with progressive NF2-derived schwannomas. Hearing improves in 2\/5 assessable patients (40%) as determined by international guidelines, with increases in word recognition scores. Tumor volume reductions of \u226520% are observed in two patients, including one in which bevacizumab had not been effective. There are no severe adverse events related to the vaccine. Both VEGFR1-specific and VEGFR2-specific CTLs are induced in six patients. Surgery is performed after vaccination in two patients, and significant reductions in the expression of\u00a0VEGFRs in schwannomas are observed. Therefore, this clinical immunotherapy study demonstrates the safety and preliminary efficacy of VEGFRs peptide vaccination in patients with NF2.<\/jats:p>","DOI":"10.1038\/s41467-019-13640-1","type":"journal-article","created":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T11:02:49Z","timestamp":1576580569000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["A VEGF receptor vaccine demonstrates preliminary efficacy in neurofibromatosis type 2"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8637-901X","authenticated-orcid":false,"given":"Ryota","family":"Tamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukina","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Ohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenzo","family":"Kosugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuto","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryo","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuro","family":"Hikichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinobu","family":"Noji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8204-9518","authenticated-orcid":false,"given":"Naoki","family":"Oishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunari","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2700-1620","authenticated-orcid":false,"given":"Masahiro","family":"Toda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"13640_CR1","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/lary.25976","volume":"126","author":"A Picry","year":"2016","unstructured":"Picry, A. et al. Long-term growth rate of vestibular schwannoma in neurofibromatosis 2: a volumetric consideration. Laryngoscope 126, 2358\u20132362 (2016).","journal-title":"Laryngoscope"},{"key":"13640_CR2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/02688690500081206","volume":"19","author":"DG Evans","year":"2005","unstructured":"Evans, D. G. et al. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. Br. J. Neurosurg. 19, 5\u201312 (2005).","journal-title":"Br. J. Neurosurg."},{"key":"13640_CR3","first-page":"22","volume":"1","author":"M Shearwood","year":"2007","unstructured":"Shearwood, M. et al. The treatment of a large acoustic tumor with fractionated stereotactic radiotherapy. J. Robot Surg. 1, 22\u201330 (2007).","journal-title":"J. Robot Surg."},{"key":"13640_CR4","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-010-0181-1","volume":"98","author":"MS Sharma","year":"2010","unstructured":"Sharma, M. S. et al. Tumor control and hearing preservation after Gamma Knife radiosurgery for vestibular schwannomas in neurofibromatosis type 2. J. Neurooncol. 98, 265\u2013270 (2010).","journal-title":"J. Neurooncol."},{"key":"13640_CR5","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3171\/2014.7.GKS141311","volume":"121","author":"C Seferis","year":"2014","unstructured":"Seferis, C. et al. Malignant transformation in vestibular schwannoma: report of a single case, literature search, and debate. J. Neurosurg. 121, 160\u2013166 (2014).","journal-title":"J. Neurosurg."},{"key":"13640_CR6","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1056\/NEJMoa0902579","volume":"361","author":"SR Plotkin","year":"2009","unstructured":"Plotkin, S. R. et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N. Engl. J. Med. 361, 358\u2013367 (2009).","journal-title":"N. Engl. J. Med."},{"key":"13640_CR7","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s10014-017-0284-x","volume":"34","author":"R Tamura","year":"2017","unstructured":"Tamura, R. et al. Bevacizumab for malignant gliomas: current indications, mechanisms of action and resistance, and markers of response. Brain Tumor Pathol. 34, 62\u201377 (2017).","journal-title":"Brain Tumor Pathol."},{"key":"13640_CR8","doi-asserted-by":"crossref","first-page":"21569","DOI":"10.18632\/oncotarget.25131","volume":"9","author":"S Shibao","year":"2018","unstructured":"Shibao, S. et al. A pilot study of peptide vaccines for VEGF receptor 1 and 2 in patients with recurrent\/progressive high grade glioma. Oncotarget 9, 21569\u201321579 (2018).","journal-title":"Oncotarget"},{"key":"13640_CR9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.wneu.2013.02.069","volume":"82","author":"YS Niknafs","year":"2014","unstructured":"Niknafs, Y. S. et al. Hemorrhagic vestibular schwannoma: review of the literature. World Neurosurg. 82, 751\u2013756 (2014).","journal-title":"World Neurosurg."},{"key":"13640_CR10","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1212\/01.wnl.0000435746.02780.f6","volume":"81","author":"SR Plotkin","year":"2013","unstructured":"Plotkin, S. R. et al. Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology 81, S25\u2013S32 (2013).","journal-title":"Neurology"},{"key":"13640_CR11","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1136\/jmg.37.12.897","volume":"37","author":"DGR Evans","year":"2000","unstructured":"Evans, D. G. R. et al. Neurofibromatosis type 2. J. Med. Genet. 37, 897\u2013904 (2000).","journal-title":"J. Med. Genet."},{"key":"13640_CR12","doi-asserted-by":"crossref","first-page":"N12","DOI":"10.1227\/01.NEU.0000345342.96663.0A","volume":"65","author":"RJ Komotar","year":"2009","unstructured":"Komotar, R. J. et al. The role of bevacizumab in hearing preservation and tumor volume control in patients with vestibular schwannomas. Neurosurgery 65, N12 (2009).","journal-title":"Neurosurgery"},{"key":"13640_CR13","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1097\/MAO.0b013e31825e73f5","volume":"33","author":"SR Plotkin","year":"2012","unstructured":"Plotkin, S. R. et al. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol. Neurotol. 33, 1046\u20131052 (2012).","journal-title":"Otol. Neurotol."},{"key":"13640_CR14","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s00405-014-3398-3","volume":"272","author":"MC Alanin","year":"2015","unstructured":"Alanin, M. C. et al. The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2. Eur. Arch. Otorhinolaryngol. 272, 3627\u20133633 (2015).","journal-title":"Eur. Arch. Otorhinolaryngol."},{"key":"13640_CR15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/neuonc\/nop010","volume":"12","author":"VF Mautner","year":"2010","unstructured":"Mautner, V. F. et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro Oncol. 12, 14\u201318 (2010).","journal-title":"Neuro Oncol."},{"key":"13640_CR16","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/RLU.0000000000000329","volume":"39","author":"MW Versleijen","year":"2014","unstructured":"Versleijen, M. W. et al. Avastin scintigraphy in surveillance of bevacizumab treatment in a patient with neurofibromatosis type 2: a case report. Clin. Nucl. Med. 39, 277\u2013280 (2014).","journal-title":"Clin. Nucl. Med."},{"key":"13640_CR17","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1212\/WNL.0000000000000997","volume":"83","author":"J Blakeley","year":"2014","unstructured":"Blakeley, J. et al. Clinical response to bevacizumab in schwannomatosis. Neurology 83, 1986\u20131987 (2014).","journal-title":"Neurology"},{"key":"13640_CR18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1200\/JCO.2011.38.2614","volume":"30","author":"V Subbiah","year":"2012","unstructured":"Subbiah, V. et al. Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. J. Clin. Oncol. 30, 64\u201368 (2012).","journal-title":"J. Clin. Oncol."},{"key":"13640_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1017\/S0022215111002805","volume":"126","author":"GK Eminowicz","year":"2012","unstructured":"Eminowicz, G. K. et al. Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy. J. Laryngol. Otol. 126, 79\u201382 (2012).","journal-title":"J. Laryngol. Otol."},{"key":"13640_CR20","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.3892\/ol.2016.4347","volume":"11","author":"P Liu","year":"2016","unstructured":"Liu, P. et al. Low-dose bevacizumab induces radiographic regression of vestibular schwannomas in neurofibromatosis type 2: a case report and literature review. Oncol. Lett. 11, 2981\u20132986 (2016).","journal-title":"Oncol. Lett."},{"key":"13640_CR21","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1349-7006.2009.01416.x","volume":"101","author":"M Miyazawa","year":"2010","unstructured":"Miyazawa, M. et al. Phase I clinical trial using peptide vaccine for human vascular endothelial growth factor receptor 2 in combination with gemcitabine for patients with advanced pancreatic cancer. Cancer Sci. 101, 433\u2013439 (2010).","journal-title":"Cancer Sci."},{"key":"13640_CR22","volume":"12","author":"S Hazama","year":"2014","unstructured":"Hazama, S. et al. A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. J. Transl. Med. 12, 63 (2014).","journal-title":"J. Transl. Med."},{"key":"13640_CR23","volume":"12","author":"S Hazama","year":"2014","unstructured":"Hazama, S. et al. A phase \u0399I study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). J. Transl. Med. 12, 108 (2014).","journal-title":"J. Transl. Med."},{"key":"13640_CR24","doi-asserted-by":"crossref","DOI":"10.1186\/1479-5876-12-84","volume":"12","author":"H Iinuma","year":"2014","unstructured":"Iinuma, H. et al. Phase I clinical study of multiple epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J. Transl. Med. 12, 84 (2014).","journal-title":"J. Transl. Med."},{"key":"13640_CR25","doi-asserted-by":"crossref","first-page":"5841","DOI":"10.1158\/1078-0432.CCR-06-0750","volume":"12","author":"H Ishizaki","year":"2006","unstructured":"Ishizaki, H. et al. Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. Clin. Cancer Res. 12, 5841\u20135849 (2006).","journal-title":"Clin. Cancer Res."},{"key":"13640_CR26","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.3892\/ijo.2012.1573","volume":"41","author":"T Masuzawa","year":"2012","unstructured":"Masuzawa, T. et al. Phase I\/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer. Int J. Oncol. 41, 1297\u20131304 (2012).","journal-title":"Int J. Oncol."},{"key":"13640_CR27","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1158\/0008-5472.CAN-04-3759","volume":"65","author":"S Wada","year":"2005","unstructured":"Wada, S. et al. Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 65, 4939\u20134946 (2005).","journal-title":"Cancer Res."},{"key":"13640_CR28","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1038\/bjc.2013.90","volume":"108","author":"K Yoshimura","year":"2013","unstructured":"Yoshimura, K. et al. Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma. Br. J. Cancer 108, 1260\u20131266 (2013).","journal-title":"Br. J. Cancer"},{"key":"13640_CR29","doi-asserted-by":"crossref","first-page":"E263","DOI":"10.3390\/jcm8020263","volume":"8","author":"R Kikuchi","year":"2019","unstructured":"Kikuchi, R. et al. A pilot study of vaccine therapy with multiple glioma oncoantigen\/glioma angiogenesis-associated antigen peptides for patients with recurrent\/progressive high-grade glioma. J. Clin. Med. 8, E263 (2019).","journal-title":"J. Clin. Med."},{"key":"13640_CR30","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3171\/2016.5.JNS153013","volume":"127","author":"AP Marston","year":"2017","unstructured":"Marston, A. P. et al. Pretreatment growth rate as a predictor of tumor control following Gamma Knife radiosurgery for sporadic vestibular schwannoma. J. Neurosurg. 127, 380\u2013387 (2017).","journal-title":"J. Neurosurg."},{"key":"13640_CR31","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1002\/eji.200939887","volume":"40","author":"H Suzuki","year":"2010","unstructured":"Suzuki, H. et al. VEGFR2 is selectively expressed by FOXP3high CD4+ Treg. Eur. J. Immunol. 40, 197\u2013203 (2010).","journal-title":"Eur. J. Immunol."},{"key":"13640_CR32","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2326-6066.CIR-16-0194","volume":"5","author":"T Kumai","year":"2017","unstructured":"Kumai, T. et al. Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol. Res. 5, 72\u201383 (2017).","journal-title":"Cancer Immunol. Res."},{"key":"13640_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2016.11.001","volume":"45","author":"T Kumai","year":"2017","unstructured":"Kumai, T. et al. Peptide vaccines in cancer-old concept revisited. Curr. Opin. Immunol. 45, 1\u20137 (2017).","journal-title":"Curr. Opin. Immunol."},{"key":"13640_CR34","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-14-0314","volume":"20","author":"S Koido","year":"2014","unstructured":"Koido, S. et al. Treatment with chemotherapy and dendritic cells pulsed with multiple Wilms\u2019 tumor 1 (WT1)-specific MHC class I\/II-restricted epitopes for pancreatic cancer. Clin. Cancer Res. 20, 4228\u20134239 (2014).","journal-title":"Clin. Cancer Res."},{"key":"13640_CR35","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1182\/blood-2007-11-120998","volume":"112","author":"P Muranski","year":"2008","unstructured":"Muranski, P. et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 112, 362\u2013373 (2008).","journal-title":"Blood"},{"key":"13640_CR36","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1126\/science.1251102","volume":"344","author":"E Tran","year":"2014","unstructured":"Tran, E. et al. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science 344, 641\u2013645 (2014).","journal-title":"Science"},{"key":"13640_CR37","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20091918","volume":"207","author":"SA Quezada","year":"2010","unstructured":"Quezada, S. A. et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J. Exp. Med. 207, 637\u2013650 (2010).","journal-title":"J. Exp. Med."},{"key":"13640_CR38","doi-asserted-by":"crossref","first-page":"4228","DOI":"10.1158\/1078-0432.CCR-13-0002","volume":"19","author":"CL Slingluff Jr","year":"2013","unstructured":"Slingluff, C. L. Jr et al. A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin. Cancer Res. 19, 4228\u20134238 (2013).","journal-title":"Clin. Cancer Res."},{"key":"13640_CR39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1084\/jem.20022235","volume":"198","author":"Y Iwai","year":"2003","unstructured":"Iwai, Y. et al. PD-1 inhibits antiviral immunity at the effector phase in the liver. J. Exp. Med. 198, 39\u201350 (2003).","journal-title":"J. Exp. Med."},{"key":"13640_CR40","doi-asserted-by":"crossref","first-page":"k3529","DOI":"10.1136\/bmj.k3529","volume":"362","author":"X Shen","year":"2018","unstructured":"Shen, X. et al. Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. BMJ 362, k3529 (2018).","journal-title":"BMJ"},{"key":"13640_CR41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3389\/fphar.2014.00287","volume":"5","author":"M Fujioka","year":"2014","unstructured":"Fujioka, M. et al. Inflammatory and immune responses in the cochlea: potential therapeutic targets for sensorineural hearing loss. Front. Pharmacol. 5, 287 (2014).","journal-title":"Front. Pharmacol."},{"key":"13640_CR42","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1084\/jem.20100438","volume":"207","author":"MJ Waldner","year":"2010","unstructured":"Waldner, M. J. et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J. Exp. Med. 207, 2855\u20132868 (2010).","journal-title":"J. Exp. Med."},{"key":"13640_CR43","doi-asserted-by":"crossref","first-page":"e59941","DOI":"10.1371\/journal.pone.0059941","volume":"8","author":"FP Nunes","year":"2003","unstructured":"Nunes, F. P. et al. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS ONE 8, e59941 (2003).","journal-title":"PLoS One"},{"key":"13640_CR44","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1055\/s-0038-1627471","volume":"38","author":"SR Plotkin","year":"2018","unstructured":"Plotkin, S. R. et al. Neurofibromatosis and schwannomatosis. Semin Neurol. 38, 73\u201385. (2018).","journal-title":"Semin Neurol."},{"key":"13640_CR45","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1212\/01.wnl.0000435744.57038.af","volume":"81","author":"E Dombi","year":"2013","unstructured":"Dombi, E. et al. REiNS International Collaboration. Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 81, S33\u2013S40 (2013).","journal-title":"Neurology"},{"key":"13640_CR46","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.4049\/jimmunol.159.5.2513","volume":"159","author":"K Fleischhauer","year":"1997","unstructured":"Fleischhauer, K. et al. Functional heterogeneity of HLA-A*02 subtypes revealed by presentation of a MAGE-3-encoded peptide to cytotoxic T cell clones. J. Immunol. 159, 2513\u20132521 (1997).","journal-title":"J. Immunol."},{"key":"13640_CR47","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1111\/j.1365-2125.2012.04179.x","volume":"73","author":"GV Goldmacher","year":"2012","unstructured":"Goldmacher, G. V. et al. The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. Br. J. Clin. Pharmacol. 73, 846\u2013854 (2012).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"13640_CR48","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1200\/JCO.2015.64.3817","volume":"34","author":"JO Blakeley","year":"2016","unstructured":"Blakeley, J. O. et al. Efficacy and biomarker study of bevacizumab for hearing loss resulting from neurofibromatosis type 2-associated vestibular schwannomas. J. Clin. Oncol. 34, 1669\u20131675 (2016).","journal-title":"J. Clin. Oncol."},{"key":"13640_CR49","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.3174\/ajnr.A2668","volume":"32","author":"TR Patel","year":"2011","unstructured":"Patel, T. R. et al. A comprehensive review of MR imaging changes following radiosurgery to 500 brain metastases. AJNR Am. J. Neuroradiol. 32, 1885\u20131892 (2011).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"13640_CR50","doi-asserted-by":"crossref","first-page":"E41","DOI":"10.3174\/ajnr.A4341","volume":"36","author":"K Welker","year":"2015","unstructured":"Welker, K. et al. ASFNR recommendations for clinical performance of MR dynamic susceptibility contrast perfusion imaging of the brain. AJNR Am. J. Neuroradiol. 36, E41\u2013E51 (2015).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"13640_CR51","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/05384916609074196","volume":"2","author":"S Horiguti","year":"1966","unstructured":"Horiguti, S. Comparison of speech audiometry test-words among various languages. Int. Audiol. 2, 275\u2013279 (1966).","journal-title":"Int. Audiol."}],"updated-by":[{"DOI":"10.1038\/s41467-020-16007-z","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,4,21]],"date-time":"2020-04-21T00:00:00Z","timestamp":1587427200000}}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13640-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13640-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T03:36:05Z","timestamp":1695526565000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13640-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,17]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13640"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13640-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41467-020-16007-z","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,17]]},"assertion":[{"value":"8 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"An amendment to this paper has been published and can be accessed via a link at the top of the paper.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.H. is an employee of OncoTherapy Science, Inc. All the other authors declare no competing interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5758"}}